Abstract
Editorials2 April 2013Statin Discontinuation and Intolerance: The Challenge of Lifelong TherapyScott M. Grundy, MD, PhDScott M. Grundy, MD, PhDFrom Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-7-201304020-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Statins are among the most widely prescribed drugs. They reduce atherosclerotic cardiovascular disease events and improve survival in patients with established disease. Recommendations virtually mandate statin use in secondary prevention and widely advocate use for primary prevention. Clinicians initiate statin therapy with the expectation that the patient will continue lifelong treatment. However, this is a tall order for many persons, and it is not surprising that discontinuation rates are relatively high (1–3). As reported in this issue, Zhang and colleagues (4) explored the frequency of discontinuing statins in 1 hospital system. Combining data from structured electronic medical records and electronic ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
